Assessment and Benchmarking of Model Informed Approaches in Drug Development for Hemoglobinopathies: A Review of Scientific Advices From January 2000 to December 2024

Documenti analoghi

• Modeling and Simulation in Development and Regulatory Approval of Chimeric Antigen Receptor T‐Cell Therapies: An Analysis of European Medicines Agency Centralized Procedures From 2018 to 2024
  di: Lisa Hanquet, et al.
  Pubblicazione: (2026)
• State‐of‐the‐Art on Model‐Informed Drug Development Approaches for Pediatric Rare Diseases
  di: Rajesh Krishna, et al.
  Pubblicazione: (2025)
• Risk Assessment for Drug‐Induced Hyperbilirubinemia: A Mechanistic Approach
  di: Rajeev Kumar, et al.
  Pubblicazione: (2026)
• The Evolving Role of In Vitro–In Vivo Correlation in Model‐Informed Drug Development: A Multi‐Stakeholder Perspective
  di: Marylore Chenel, et al.
  Pubblicazione: (2025)
• Integration of Machine Learning With PBPK and QSAR Modeling Approaches to Facilitate Drug Discovery and Development
  di: Xinyue Chen, et al.
  Pubblicazione: (2026)